Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...

On November 24, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab ...

In the US, the company had earlier secured market entry dates for its Denosumab biosimilars Bosaya™ (denosumab-kyqq) and ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

Biocon Biologics settles with Amgen to commercialize Denosumab biosimilars (Vevzuo & Evfraxy) in Europe starting Dec 2, 2025.

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

Biocon Biologics finalises an agreement with Amgen Inc., enabling commercialisation of Denosumab biosimilars Vevzuo and ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

Biocon Biologics and Amgen settle to commercialize Denosumab biosimilars in Europe, expanding access to affordable biologics.

Bengaluru: Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...

Australia’s Therapeutic Goods Administration (TGA) has issued a safety warning regarding the discontinuation of Prolia ...